Clinical Trials · NCT01632163
Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 447
- Start date
- Oct 2012
- Locations
- 51 sites, 4 countries
- Primary endpoint
- Change in HbA1c